{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T21:41:50Z","timestamp":1773265310571,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Conventional implantable cardioverter-defibrillators (ICDs) and pacemakers carry a\u00a0risk of pocket- and lead-related complications in particular. To avoid these complications, extravascular devices (EVDs) have been developed, such as the subcutaneous ICD (S-ICD) and leadless pacemaker (LP). However, data on patient or centre characteristics related to the actual adoption of EVDs are lacking.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To assess real-world nationwide trends in EVD adoption in the Netherlands.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using the Netherlands Heart Registration, all consecutive patients with a\u00a0de novo S\u2011ICD or conventional single-chamber ICD implantation between 2012\u20132020, or de novo LP or conventional single-chamber pacemaker implantation between 2014\u20132020 were included. Trends in adoption are described for various patient and centre characteristics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Result<\/jats:title>\n                <jats:p>From 2012\u20132020, 2190 S\u2011ICDs and 10,683 conventional ICDs were implanted; from 2014\u20132020, 712 LPs and 11,103 conventional pacemakers were implanted. The general use has increased (S-ICDs 8 to 21%; LPs 1 to 8%), but this increase seems to have reached a\u00a0plateau. S\u2011ICD recipients were younger than conventional ICD recipients (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090.001) and more often female (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090.001); LP recipients were younger than conventional pacemaker recipients (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090.001) and more often male (<jats:italic>p<\/jats:italic>\u202f=\u20090.03). Both S\u2011ICDs and LPs were mainly implanted in high-volume centres with cardiothoracic surgery on-site, although over time S\u2011ICDs were increasingly implanted in centres without cardiothoracic surgery (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This nationwide study demonstrated a\u00a0relatively quick adoption of innovative EVDs with a\u00a0plateau after approximately 4\u00a0years. S\u2011ICD use is especially high in younger patients. EVDs are mainly implanted in high-volume centres with cardiothoracic surgery back-up, but S\u2011ICD use is expanding beyond those centres.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12471-024-01892-6","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T13:02:42Z","timestamp":1724072562000},"page":"356-362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Trends in adoption of extravascular cardiac implantable electronic devices: the Dutch cohort"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8637-2099","authenticated-orcid":false,"given":"Karel T. N.","family":"Breeman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinoud E.","family":"Knops","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle D.","family":"van der Stoel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas V. A.","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sing-Chien","family":"Yap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieselot","family":"van Erven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent F.","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander H.","family":"Maass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur A. M.","family":"Wilde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fleur V. Y.","family":"Tjong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Device Registration Committee of the Netherlands Heart Registration","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"key":"1892_CR1","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.hrthm.2011.12.014","volume":"9","author":"EO Udo","year":"2012","unstructured":"Udo\u00a0EO, Zuithoff\u00a0NP, van Hemel\u00a0NM, et\u00a0al. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. Heart Rhythm. 2012;9:728\u201335.","journal-title":"Heart Rhythm"},{"key":"1892_CR2","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/eurheartj\/eht511","volume":"35","author":"RE Kirkfeldt","year":"2014","unstructured":"Kirkfeldt\u00a0RE, Johansen\u00a0JB, Nohr\u00a0EA, J\u00f8rgensen\u00a0OD, Nielsen\u00a0JC. Complications after cardiac implantable electronic device implantations: an analysis of a\u00a0complete, nationwide cohort in Denmark. Eur Heart\u00a0J. 2014;35:1186\u201394.","journal-title":"Eur Heart J"},{"key":"1892_CR3","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1056\/NEJMoa1915932","volume":"383","author":"RE Knops","year":"2020","unstructured":"Knops\u00a0RE, Olde Nordkamp\u00a0LRA. Delnoy P\u2011PHM, et\u00a0al. Subcutaneous or Transvenous Defibrillator Therapy. New Engl J Med. 2020;383:526\u201336.","journal-title":"New Engl J Med"},{"key":"1892_CR4","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/jce.15863","volume":"34","author":"GH Crossley","year":"2023","unstructured":"Crossley\u00a0GH, Piccini\u00a0JP, Longacre\u00a0C, Higuera\u00a0L, Stromberg\u00a0K, El-Chami\u00a0MF. Leadless versus transvenous single-chamber ventricular pacemakers: 3\u00a0year follow-up of the Micra CED study. J\u00a0Cardiovasc Electrophysiol. 2023;34:1015\u201323.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1892_CR5","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/jce.13498","volume":"29","author":"A-FBE Quast","year":"2018","unstructured":"Quast\u00a0A\u2011FBE, van Dijk\u00a0VF, Yap\u00a0S\u2011C, et\u00a0al. Six-year follow-up of the initial Dutch subcutaneous implantable cardioverter-defibrillator cohort: Long-term complications, replacements, and battery longevity. J\u00a0Cardiovasc Electrophysiol. 2018;29:1010\u20136.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1892_CR6","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.hrthm.2023.05.031","volume":"20","author":"KTN Breeman","year":"2023","unstructured":"Breeman\u00a0KTN, Oosterwerff\u00a0EFJ, de Graaf\u00a0MA, et\u00a0al. Five-year safety and efficacy of leadless pacemakers in a\u00a0Dutch cohort. Heart Rhythm. 2023;20:1128\u201335.","journal-title":"Heart Rhythm"},{"key":"1892_CR7","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s12471-022-01672-0","volume":"30","author":"MJC Timmermans","year":"2022","unstructured":"Timmermans\u00a0MJC, Houterman\u00a0S, Daeter\u00a0ED, et\u00a0al. Using real-world data to monitor and improve quality of care in coronary artery disease: results from the Netherlands heart registration. Neth Heart\u00a0J. 2022;30:546\u201356.","journal-title":"Neth Heart J"},{"key":"1892_CR8","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1001\/jamacardio.2016.2782","volume":"1","author":"DJ Friedman","year":"2016","unstructured":"Friedman\u00a0DJ, Parzynski\u00a0CS, Varosy\u00a0PD, et\u00a0al. Trends and in-hospital outcomes associated with adoption of the subcutaneous Implantable cardioverter defibrillator in the United States. JAMA Cardiol. 2016;1:900\u201311.","journal-title":"JAMA Cardiol"},{"key":"1892_CR9","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.hrthm.2022.02.006","volume":"19","author":"R Tonegawa-Kuji","year":"2022","unstructured":"Tonegawa-Kuji\u00a0R, Inoue\u00a0YY, Nakai\u00a0M, et\u00a0al. Current clinical practice of subcutaneous implantable cardioverter-defibrillator: Analysis using the JROAD-DPC database. Heart Rhythm. 2022;19:909\u201316.","journal-title":"Heart Rhythm"},{"key":"1892_CR10","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/europace\/euy009","volume":"20","author":"S Boveda","year":"2018","unstructured":"Boveda\u00a0S, Lenarczyk\u00a0R, Fumagalli\u00a0S, et\u00a0al. Factors influencing the use of subcutaneous or transvenous implantable cardioverter-defibrillators: results of the European Heart Rhythm Association prospective survey. Europace. 2018;20:887\u201392.","journal-title":"Europace"},{"key":"1892_CR11","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.jacc.2012.07.017","volume":"60","author":"AJ Greenspon","year":"2012","unstructured":"Greenspon\u00a0AJ, Patel\u00a0JD, Lau\u00a0E, et\u00a0al. Trends in permanent pacemaker implantation in the United States from 1993 to 2009: increasing complexity of patients and procedures. J\u00a0Am Coll Cardiol. 2012;60:1540\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"1892_CR12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/jce.15343","volume":"33","author":"RG Hauser","year":"2022","unstructured":"Hauser\u00a0RG, Gornick\u00a0CC, Abdelhadi\u00a0RH, et\u00a0al. Leadless pacemaker perforations: Clinical consequences and related device and user problems. J\u00a0Cardiovasc Electrophysiol. 2022;33:154\u20139.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1892_CR13","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/eurheartj\/ehae101","volume":"45","author":"MF El-Chami","year":"2024","unstructured":"El-Chami\u00a0MF, Garweg\u00a0C, Clementy\u00a0N, et\u00a0al. Leadless pacemakers at 5\u2011year follow-up: the Micra transcatheter pacing system post-approval registry. Eur Heart\u00a0J. 2024;45:1241\u201351.","journal-title":"Eur Heart J"},{"key":"1892_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/joa3.12811","volume":"39","author":"PR Roberts","year":"2023","unstructured":"Roberts\u00a0PR, Cl\u00e9menty\u00a0N, Mondoly\u00a0P, et\u00a0al. A\u00a0leadless pacemaker in the real-world setting: Patient profile and performance over time. J\u00a0Arrhythm. 2023;39:1\u20139.","journal-title":"J Arrhythm"},{"key":"1892_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.hrthm.2023.09.017","volume":"21","author":"G Crossley","year":"2024","unstructured":"Crossley\u00a0G, Longacre\u00a0C, Higuera\u00a0L, et\u00a0al. Outcomes of Patients Implanted with an Atrioventricular Synchronous Leadless Ventricular Pacemaker in the Medicare Population. Heart Rhythm. 2024;21:66\u201373.","journal-title":"Heart Rhythm"},{"key":"1892_CR16","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1056\/NEJMoa2206485","volume":"387","author":"P Friedman","year":"2022","unstructured":"Friedman\u00a0P, Murgatroyd\u00a0F, Boersma\u00a0LVA, et\u00a0al. Efficacy and safety of an extravascular Implantable cardioverter-defibrillator. N\u00a0Engl J Med. 2022;387:1292\u2013302.","journal-title":"N Engl J Med"},{"key":"1892_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.hrthm.2022.01.024","volume":"19","author":"KTN Breeman","year":"2022","unstructured":"Breeman\u00a0KTN, Swackhamer\u00a0B, Brisben\u00a0AJ, et\u00a0al. Long-term performance of a\u00a0novel communicating antitachycardia pacing-enabled leadless pacemaker and subcutaneous implantable cardioverter-defibrillator system: A\u00a0comprehensive preclinical study. Heart Rhythm. 2022;19:837\u201346.","journal-title":"Heart Rhythm"},{"key":"1892_CR18","unstructured":"Effectiveness of the EMPOWER\u2122 Modular Pacing System and EMBLEM\u2122 Subcutaneous ICD to Communicate Antitachycardia Pacing (MODULAR ATP). https:\/\/clinicaltrials.gov\/study\/NCT04798768"},{"key":"1892_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.hrthm.2021.06.1195","volume":"19","author":"T Okabe","year":"2022","unstructured":"Okabe\u00a0T, Hummel\u00a0JD, Bank\u00a0AJ, et\u00a0al. Leadless left ventricular stimulation with WiSE-CRT System\u2014Initial experience and results from phase\u00a0I of SOLVE-CRT Study (nonrandomized, roll-in phase). Heart Rhythm. 2022;19:22\u20139.","journal-title":"Heart Rhythm"},{"key":"1892_CR20","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1056\/NEJMoa2300080","volume":"388","author":"RE Knops","year":"2023","unstructured":"Knops\u00a0RE, Reddy\u00a0VY, Ip\u00a0JE, et\u00a0al. A\u00a0Dual-Chamber Leadless Pacemaker. New Engl J Med. 2023;388:2360\u201370.","journal-title":"New Engl J Med"},{"key":"1892_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s12471-023-01768-1","volume":"31","author":"FVY Tjong","year":"2023","unstructured":"Tjong\u00a0FVY, Breeman\u00a0KTN, Boersma\u00a0LVA, et\u00a0al. NL-EVDR: Netherlands-extraVascular device registry. Neth Heart\u00a0J. 2023;31:181\u20134.","journal-title":"Neth Heart J"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-024-01892-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-024-01892-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-024-01892-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T11:41:42Z","timestamp":1726746102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-024-01892-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1892"],"URL":"https:\/\/doi.org\/10.1007\/s12471-024-01892-6","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]},"assertion":[{"value":"15 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of interest"}},{"value":"K.T.N.\u00a0Breeman received an unrestricted research grant from Medtronic. R.E.\u00a0Knops received consulting honoraria from Abbott, Boston Scientific, Medtronic, and Cairdac and has stock options from AtaCor Medical Inc. L.V.A.\u00a0Boersma received consulting honoraria, paid to his institution, from Medtronic, Boston Scientific, Abbott, Philips and Acutus, has served on a\u00a0steering committee for the EMPOWER and EV-ICD trials and as an editor for the Netherlands Heart Journal. S.-C.\u00a0Yap received institutional research grants and honoraria from Boston Scientific, Medtronic and Biotronik. A.H.\u00a0Maass received consulting honoraria, paid to his institution, from Boston Scientific and Medtronic. F.V.Y.\u00a0Tjong F.V.Y.\u00a0Tjong received consulting honoraria from Abbott and Boston Scientific, paid to her institution (no personal financial gain) and support from the Dutch Research Council (NWO Rubicon grant number 452019308) and Amsterdam Cardiovascular Sciences. M.D.\u00a0van der Stoel, L.\u00a0van Erven, V.F.\u00a0van Dijk and A.A.M.\u00a0Wilde declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}